Bayer sets ambitious growth and earnings aspirations

Further sales and earnings growth pursued in all businesses / Combined peak annual sales potential of recently launched pharmaceutical products raised to over EUR 10 billion / Six further product candidates in the Pharmaceuticals pipeline have combined peak sales potential of at least EUR 6 billion / Strong brands driving business at Consumer Health / Above-market sales growth and substantial margin increases expected at Crop Science following the closing of the agreed acquisition of Monsanto
Source: Bayer Company News - Category: Pharmaceuticals Source Type: news